Cautious Outlook on Amgen: Sell Rating Amid Modest Growth and ...

1 day ago · In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a price target of $275.00. Maximize …

CouponFollow Extension

$275.00
OFF

Cautious Outlook On Amgen: Sell Rating Amid Modest Growth And ...

2 weeks from now

1 day ago · In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a price target of $275.00. Maximize …

tipranks.com

$256.00
OFF

Amgen’s Sell Rating: Declining EPS And Overvalued Stock Amid …

2 weeks from now

Jan 30, 2025 · In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a price target of $256.00. …

businessinsider.com

$295
OFF

Are Wall Street Analysts Predicting Amgen Stock Will Climb Or Sink?

2 weeks from now

3 days ago · On Jan. 28, Citi lowered its price target on Amgen to $295, maintaining a “Neutral” rating due to a more challenging biotech sector outlook in 2025. As of writing, AMGN is trading …

nasdaq.com

05%
OFF

2 Reasons To Buy Amgen Stock, And 1 Reason To Be Cautious

2 weeks from now

Nov 16, 2024 · While Amgen's (AMGN 0.05%) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, …

fool.com

$215.00
OFF

Amgen Faces Financial Headwinds: Sell Rating Justified Amid …

2 weeks from now

Aug 9, 2024 · Brian Skorney, an analyst from Robert W. Baird, maintained the Sell rating on Amgen (AMGN – Research Report). The associated price target is $215.00. The associated …

businessinsider.com

5%
OFF

Amgen Earnings: Raising Our Fair Value By 5% On Solid

2 weeks from now

2 days ago · Amgen reported $33.4 billion in revenue (19% growth, boosted by the Horizon acquisition) and $19.84 in non-GAAP earnings per share (6% growth) for 2024. 2025 guidance …

morningstar.com

49%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Nov 29, 2024 · Shares of Amgen (AMGN 0.49%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially …

fool.com

19%
OFF

Amgen Q4: Good Quarter, Ok Guidance, But MariTide Concerns …

2 weeks from now

1 day ago · Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

seekingalpha.com

$20.60
OFF

Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs

2 weeks from now

3 days ago · The midpoint of the outlook, $20.60, lagged analysts' call for $20.92, according to FactSet. But the middle of Amgen's sales guidance for $34.3 billion to $35.7 billion came in …

investors.com

FAQs about Cautious Outlook on Amgen: Sell Rating Amid Modest Growth and ... Coupon?

Is Amgen (Amgen) a good stock to buy?

Overall, Risinger’s Hold rating reflects a balanced view of Amgen’s current position and its potential for growth against the backdrop of certain uncertainties and pending milestones. In another report released on February 22, Bank of America Securities also maintained a Hold rating on the stock with a $315.00 price target. ...

Should you buy Amgen (AMGN)?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 12 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. ...

What is the average price target for Amgen?

According to the 27 analysts' twelve-month price targets for Amgen, the average price target is $314.00. The highest price target for AMGN is $405.00, while the lowest price target for AMGN is $195.00. The average price target represents a forecasted upside of 8.70% from the current price of $288.87. ...

Is jhvephoto Amgen (AMGN) a good stock to buy?

JHVEPhoto Amgen (NASDAQ:AMGN) is a company that is really suitable for long-term investment (especially for dividend investors) with its clinical developments and financial performance. However there are still some factors that call for a cautious approach to the stock right now. Iwill explain in detail why I am a "hold" on the stock. ...

Is Amgen a good Pharma pick for 2025?

A dividend yield today of 3.3% is another plus point. However, all things considered, I no longer rate Amgen as a top three Pharma pick for 2025 - my choices would be Novo, Regeneron, and A.N. Other - so I am downgrading my rating to a Hold. ...

Who owns Amgen Inc?

It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN. ...